Jefferies sets $41 price target for Beam Therapeutics, highlighting BEAM-302's potential as one-time treatment for rare genetic disease with $2.5B peak sales opportunity.
Cidara's long-acting non-vaccine drug, CD388, has received FDA Breakthrough Therapy designation for preventing seasonal influenza in vulnerable adults and adolescents.
Telomir's experimental drug, Telomir-1, kills aggressive TNBC cells. It targets their high dependence on iron and energy, exploiting a key weakness.
Novo Nordisk has agreed to acquire clinical-stage Akero Therapeutics for up to $5.2 billion to integrate efruxifermin (EFX), a promising late-stage treatment for MASH, complementing Novo Nordisk's leadership in cardiometabolic disease.
Bank of America initiates coverage of Scholar Rock with Buy rating and $53 price target, citing apitegromab's breakthrough potential in spinal muscular atrophy treatment with $2B peak sales forecast.
BofA upgrades Pharvaris to Neutral ($27 target). Unique oral drug for angioedema treatment, but current price assumes success of upcoming data.
